Longitudinal modeling of frontal cognition in APOE ϵ4 homozygotes, heterozygotes, and noncarriers

Neurology

Volumn 76, Issue 16, 2011, Pages 1383-1388

  Caselli, R J ^a,f   Dueck, A C ^b   Locke, D E C ^c,f   Hoffman Snyder, C R ^a,f   Woodruff, B K ^a,f   Rapcsak, S Z ^d,f,g   Reiman, E M ^e  

^a MAYO CLINIC   (United States)

^b Departments of Biostatistics   (United States)

^c MAYO CLINIC   (United States)

^d Departments of Neurology   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^g SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMNESIA; APOE EPSILON4 GENE; ARTICLE; AUDITORY VERBAL LEARNING TEST; COGNITION; EDUCATION; FEMALE; FRONTAL LOBE; GENDER; GENE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL TEST; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NEUROPSYCHOLOGICAL TEST; PACED AUDITORY SERIAL ATTENTION TASK; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROBLEM SOLVING; WECHSLER INTELLIGENCE SCALE; WORKING MEMORY;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COGNITION DISORDERS; DEMENTIA; FEMALE; FRONTAL LOBE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; VERBAL LEARNING;

EID: 79955395618     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182167147     Document Type: Article

References (38)

1. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106:6820-6825.
2. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated B-amyloid deposition in elderly subjects. Brain 2008;132: 1310-1323.
3. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27: 6174-6184. (Pubitemid 46890033)
4. Villemagne VL, Pike KE, Darby D, et al. AB deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008;46:1688-1697.
5. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinno JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009;72:1504-1511.
6. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807-815.
7. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
8. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloidbeta peptide: a case report. Nat Med 2003;9:448-452. (Pubitemid 36460079)
9. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009;361:255-263.
10. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125-127. (Pubitemid 24270522)
11. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurol 1984;34:939-944. (Pubitemid 14076461)
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
14. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment, 4th edition. New York: Oxford University Press; 2004.
15. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science 1997;275:1293-1295. (Pubitemid 27114154)
16. Torralva T, Roca M, Gleichgerracht E, Bekinschtein T, Manes F. A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia. Brain 2009;132:1299-1309.
17. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis (Section 15.4). Hoboken: John Wiley & Sons, Inc.; 2004.
18. Ware JH, Dockery DW, Louis TA, Xu X, Ferris BG, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 1990;132:685-700. (Pubitemid 20344536)
19. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of AD in late onset families. Science 1993;261:921-923. (Pubitemid 23275809)
20. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele 4 with late onset familial and sporadic Alzheimer's disease. Neurology 1993;43: 1467-1472. (Pubitemid 23230526)
21. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age, Ann Neurol 2009;65:650-657.
22. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
23. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866-2875. (Pubitemid 46438992)
24. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.
25. Wu HY, Hudry E, Hashimoto T, et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 2010;30:2636-2649.
26. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid B-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577. (Pubitemid 30161512)
27. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to B-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002;99:6364-6369.
28. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid B-induced deficits in Alzheimer's disease mouse model. Science 2007;316:750-754. (Pubitemid 46717684)
29. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-B toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-397.
30. Wolk DA, Dickerson BC. ADNI. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci USA 2010;107:10256-10261.
31. West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull 1996;120:272-292. (Pubitemid 126690074)
32. Verhaeghen P, Cerella J. Aging, executive control, and attention: a review of meta-analyses. Neurosci Behav Rev 2002;26:849-857. (Pubitemid 35430288)
33. Treitz FH, Heyder K, Daum I. Differential course of executive control changes during normal aging. Aging Neuropsychol Cogn 2007;14:370-393. (Pubitemid 47027108)
34. Preclinical Alzheimer's Disease Workgroup. Criteria for Preclinical Alzheimer's Disease. National Institute on Aging and the Alzheimer's Disease and Related Disorders Association; 2010.
35. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment, and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
36. Bouras C, Hof PR, Giannakopoulos P, Michel J-P, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 1994;4:138-150. (Pubitemid 24127824)
37. Braak H, Braak E. Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 1997;18:351-357. (Pubitemid 27435070)
38. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170. (Pubitemid 14029099)